Every story in this section, newest first — page 44 of 373.
FreeCast (NASDAQ:CAST) filed its Annual Report on Form 10-K for the fiscal year ended June 30, 2026, highlighting progress in its transition from technology development toward commercial deployment of its Platform-as-a-Service (PaaS) strategy.
Tesla’s (NASDAQ:TSLA) Full Self-Driving (FSD) system is facing regulatory scrutiny in Europe after the European Transport Safety Council (ETSC) urged European Union member states to reject approval of the driver-assistance technology.
Jaguar Health (NASDAQ:JAGX) announced that an abstract covering preliminary results from an adult short bowel syndrome study has been accepted for presentation at the American College of Gastroenterology (ACG) 2026 meeting.
Pearson (NYSE:PSO) agreed to acquire Workera, a company that provides AI-powered workforce skills assessment solutions for enterprises.
HUTCHMED (NASDAQ:HCM) announced that AstraZeneca (NASDAQ:AZN) submitted a U.S. regulatory application for ORPATHYS in combination with TAGRISSO for patients with MET-driven EGFR-mutated non-small cell lung cancer.
Quantum-Si (NASDAQ:QSI) reported interim results showing that its developmental Proteus protein-sequencing platform outperformed its Platinum Pro system across multiple performance measures.
Hormel Foods (NYSE:HRL) declared a quarterly common-stock dividend of $0.2925 per share, continuing the company’s long history of returning capital to shareholders.
Evotec (NASDAQ:EVO) announced that Chief Scientific Officer Cord Dohrmann will step down from his role on September 30, 2026, by mutual consent.
Novo Nordisk (NYSE:NVO) agreed to license Hengrui Pharma’s phase 1-ready oral candidate HRS-1596 in a transaction valued at up to $2.6 billion.
Eli Lilly (NYSE:LLY) reported an indirect comparison suggesting that Foundayo 17.2 mg produced greater weight loss and A1C reduction than oral semaglutide 25 mg in adults with type 2 diabetes.
Opengear, a Digi International company (NASDAQ:DGII), signed its first pan-European distribution agreement with Ingram Micro to expand access to its out-of-band management solutions across Europe.
InterGroup (NASDAQ:INTG) reported fiscal 2026 financial results, returning to GAAP profitability as improvements in its hotel operations contributed to stronger performance.
TC Energy (NYSE:TRP) announced that it will move forward with Coastal GasLink Phase 2 after LNG Canada’s expansion investment decision satisfied the required project conditions
MongoDB (NASDAQ:MDB) shares fell more than 20% after CEO and president Chirantan “CJ” Desai resigned to join Meta Platforms.
OMS Energy Technologies (NASDAQ:OMSE) secured US$9.4 million in new orders from Saudi Aramco and Pertamina Hulu Rokan for oilfield equipment and components.
FTAI Aviation (NASDAQ:FTAI) acquired 27 Boeing 737-700 aircraft from WestJet, with the purchase divided between its 2026 SPV investment vehicle and Aerospace Products business.
FTAI Infrastructure (NASDAQ:FIP) subsidiary Jefferson agreed to acquire crude oil logistics assets from a USD Group subsidiary for approximately $255 million in cash.
Psyence BioMed (NASDAQ:PBM) announced that its Texas subsidiary signed a binding term sheet with PsyLabs for proposed exclusive U.S. ibogaine rights.
Eldorado Gold (NYSE:EGO) completed the permanent connection of its Skouries mine in northern Greece to the national power grid after final inspections and approvals.
Adicet Bio (NASDAQ:ACET) reported Phase 1 safety and efficacy data for prulacabtagene leucel (prula-cel) in patients with systemic lupus erythematosus with or without lupus nephritis.
Grafa is streaming live from Marina Bay Sands on 7 and 8 October. Watch right here as we sit down with the founders, investors and builders shaping where crypto goes next.
BlossomHill Therapeutics (NASDAQ:BLSM) presented preclinical findings for BH-501284, an investigational pan-KRAS inhibitor, showing activity across KRAS-mutant cancer models.
OSI Systems (NASDAQ:OSIS) received orders of approximately $7 million from a leading industrial controls original equipment manufacturer for electronic sub-assemblies.
Merck (NYSE:MRK) entered an exclusive global license agreement with SciBrunch Therapeutics for SPR2015, a preclinical oral KRAS G12D inhibitor being developed for potential cancer treatments.
